Home > Product Storage and Stability Information > GlucaGen® Analogues and Insulins
GlucaGen® Analogues and Insulins
Explore other therapeutic areas
Before Reconstitution:
The GlucaGen® package may be stored up to 24 months at controlled room temperature (68°F - 77°F/20°C - 25°C) prior to reconstitution. Avoid freezing GlucaGen® and protect it from light by keeping it in the original package. GlucaGen® should not be used after the expiration date on the vials.1
After Reconstitution:
Reconstituted GlucaGen® should be used immediately. Discard any unused portion. If the solution shows any sign of gel formation or particles, it should be discarded.1
After the product is manufactured, Novo Nordisk Inc. stores and transports GlucaGen® HypoKit® under refrigerated conditions (36°F - 46°F/2°C - 8°C) since maintaining controlled room temperature conditions may be difficult during shipping. Refrigerating the product will not damage it; however, freezing of the product should be avoided.1
Store Zegalogue® in a refrigerator, 2°C to 8°C (36°F to 46°F). Keep away from the cooling element and do not freeze. Zegalogue® can be kept at room temperature between 20°C to 25°C (68°F to 77°F) for up to 12 months. Record the date when the product was removed from the refrigerator in the space provided on the protective case.2
Do not return the product to the refrigerator after storing at room temperature. Store in the provided protective case and protect from light. Discard Zegalogue® after the end of the 12-month period at room temperature storage, or after the expiration date stated on the product, whichever occurs first.2
Insulins
Unused (unopened) insulin vials, devices, or cartridges inadvertently left at room temperature can be returned to refrigeration but must be used within designated days of initially being stored at room temperature (see Tables 1 and 2). Products not used within the listed time periods should be discarded.
Table 1. Recommended Storage Conditions for Insulin Analogs3-7
Product
Before First Use
Room temperature
(below 86°F)a,b
Refrigerated
(36°F - 46°F)
After First Use
Room temperature
(below 86°F)a
Refrigerated
(36°F - 46°F)
NovoLog® vial (insulin aspart) injection
28 days
Until expiration date
28 days
28 days
NovoLog® FlexPen® (insulin aspart) injection
28 days
Until expiration date
28 days
N/Ac
NovoLog® FlexTouch®d (insulin aspart) injection
28 days
Until expiration date
28 days
N/Ac
NovoLog® PenFill® (insulin aspart) injection
28 days
Until expiration date
28 days
N/Ac
NovoLog® Mix 70/30 vial (70% insulin aspart protamine and 30% insulin aspart) injectable suspension
28 days
Until expiration date
28 days
28 days
NovoLog® Mix 70/30 FlexPen® (70% insulin aspart protamine and 30% insulin aspart) injectable suspension
14 days
Until expiration date
14 days
N/Ac
Fiasp® vial (insulin aspart) injection
28 days
Until expiration date
28 days
28 days
Fiasp® FlexTouch® (insulin aspart) injection
28 days
Until expiration date
28 days
28 days
Levemir® vial (insulin detemir) injection
42 days
Until expiration date
42 days
42 days
Levemir® FlexTouch® (insulin detemir) injection
42 days
Until expiration date
42 days
N/Ac
Tresiba® U-100 and U-200 FlexTouch® (insulin degludec) injection
56 days
Until expiration date
56 days
56 days
NovoLog® vial (insulin aspart) injection
Before First Use
Room temperature
(below 86°F)a,b
28 days
Refrigerated (36°F - 46°F)
Until expiration date
After First Use
Room temperature
(below 86°F)a
28 days
Refrigerated (36°F - 46°F)
28 days
NovoLog® FlexPen® (insulin aspart) injection
Before First Use
Room temperature
(below 86°F)a,b
28 days
Refrigerated (36°F - 46°F)
Until expiration date
After First Use
Room temperature
(below 86°F)a
28 days
Refrigerated (36°F - 46°F)
N/Ac
NovoLog® FlexTouch®d (insulin aspart) injection
Before First Use
Room temperature
(below 86°F)a,b
28 days
Refrigerated (36°F - 46°F)
Until expiration date
After First Use
Room temperature
(below 86°F)a
28 days
Refrigerated (36°F - 46°F)
N/Ac
NovoLog® PenFill® (insulin aspart) injection
Before First Use
Room temperature
(below 86°F)a,b
28 days
Refrigerated (36°F - 46°F)
Until expiration date
After First Use
Room temperature
(below 86°F)a
28 days
Refrigerated (36°F - 46°F)
N/Ac
NovoLog® Mix 70/30 vial (70% insulin aspart protamine and 30% insulin aspart) injectable suspension
Before First Use
Room temperature
(below 86°F)a,b
28 days
Refrigerated (36°F - 46°F)
Until expiration date
After First Use
Room temperature
(below 86°F)a
28 days
Refrigerated (36°F - 46°F)
28 days
NovoLog® Mix 70/30 FlexPen® (70% insulin aspart protamine and 30% insulin aspart) injectable suspension
Before First Use
Room temperature
(below 86°F)a,b
14 days
Refrigerated (36°F - 46°F)
Until expiration date
After First Use
Room temperature
(below 86°F)a
14 days
Refrigerated (36°F - 46°F)
N/Ac
Fiasp® vial (insulin aspart) injection
Before First Use
Room temperature
(below 86°F)a,b
28 days
Refrigerated (36°F - 46°F)
Until expiration date
After First Use
Room temperature
(below 86°F)a
28 days
Refrigerated (36°F - 46°F)
28 days
Fiasp® FlexTouch® (insulin aspart) injection
Before First Use
Room temperature
(below 86°F)a,b
28 days
Refrigerated (36°F - 46°F)
Until expiration date
After First Use
Room temperature
(below 86°F)a
28 days
Refrigerated (36°F - 46°F)
28 days
Levemir® vial (insulin detemir) injection
Before First Use
Room temperature
(below 86°F)a,b
42 days
Refrigerated (36°F - 46°F)
Until expiration date
After First Use
Room temperature
(below 86°F)a
42 days
Refrigerated (36°F - 46°F)
42 days
Levemir® FlexTouch® (insulin detemir) injection
Before First Use
Room temperature
(below 86°F)a,b
42 days
Refrigerated (36°F - 46°F)
Until expiration date
After First Use
Room temperature
(below 86°F)a
42 days
Refrigerated (36°F - 46°F)
N/Ac
Tresiba® U-100 and U-200 FlexTouch® (insulin degludec) injection
Before First Use
Room temperature
(below 86°F)a,b
56 days
Refrigerated (36°F - 46°F)
Until expiration date
After First Use
Room temperature
(below 86°F)a
56 days
Refrigerated (36°F - 46°F)
56 days
aUnrefrigerated products should be discarded if not used within the time periods listed, whether or not they have been punctured or are in-use.
bUnused (unopened) FlexTouch®, FlexPen® and NovoLog® PenFill® inadvertently left at room temperature can be returned to refrigeration but must be used within designated days of initially being stored at room temperature.
cOnce in use, should be stored at room temperatures below 86°F.
dNovoLog® FlexTouch® is not currently available in the United States.
Table 2. Recommended Storage Conditions for Insulin Analogs8-10
Product
Before First Use
Room temperature
(below 77°F)a,e
Refrigerated
(36°F - 46°F)
After First Use
Room temperature
(below 77°F)a
Refrigerated
(36°F - 46°F)
Novolin® R vial (including ReliOn® brand)f
42 days
Until expiration date
42 days
N/Ag
Novolin® N vial (including ReliOn® brand)f
42 days
Until expiration date
42 days
N/Ag
Novolin® 70/30 vial (including ReliOn® brand)f
42 days
Until expiration date
42 days
N/Ag
Novolin® R vial (including ReliOn® brand)f
Before First Use
Room temperature
(below 77°F)a,e
42 days
Refrigerated (36°F - 46°F)
Until expiration date
After First Use
Room temperature
(below 77°F)a
42 days
Refrigerated (36°F - 46°F)
N/Ag
Novolin® N vial (including ReliOn® brand)f
Before First Use
Room temperature
(below 77°F)a,e
42 days
Refrigerated (36°F - 46°F)
Until expiration date
After First Use
Room temperature
(below 77°F)a
42 days
Refrigerated (36°F - 46°F)
N/Ag
Novolin® 70/30 vial (including ReliOn® brand)f
Before First Use
Room temperature
(below 77°F)a,e
42 days
Refrigerated (36°F - 46°F)
Until expiration date
After First Use
Room temperature
(below 77°F)a
42 days
Refrigerated (36°F - 46°F)
N/Ag
eUnused (unopened) product inadvertently left at room temperature can be returned to refrigeration but must be used within designated days of initially being stored at room temperature.
fReliOn® brand is manufactured by Novo Nordisk and sold exclusively at Walmart and Sam's Club Pharmacies.
gOnce in use, Novolin® vials and Novolin®/ReliOn® vials should not be refrigerated.
References
- GlucaGen® Prescribing Information. Plainsboro, NJ: Novo Nordisk Inc.
- Zegalogue® Prescribing Information. Plainsboro, NJ. Novo Nordisk Inc.
- NovoLog® Prescribing Information. Plainsboro, NJ: Novo Nordisk Inc.
- NovoLog® Mix 70/30 Prescribing Information. Plainsboro, NJ. Novo Nordisk Inc.
- Fiasp® Prescribing Information. Plainsboro, NJ: Novo Nordisk Inc.
- Levemir® Prescribing Information. Plainsboro, NJ: Novo Nordisk Inc.
- Tresiba® Prescribing Information. Plainsboro, NJ: Novo Nordisk Inc.
- Novolin® R Prescribing Information. Plainsboro, NJ: Novo Nordisk Inc.
- Novolin® N Patient Package Insert. Plainsboro, NJ: Novo Nordisk Inc.
- Novolin® 70/30 Patient Package Insert. Plainsboro, NJ: Novo Nordisk Inc.
Find more information
Speak to a medical representative
If you are a healthcare provider from the United States, click below to request information directly from the Novo Nordisk Medical Information department. If you are a patient, please visit here to contact us, or call 1-800-727-6500.
Search the Medical Information Database
The Scientific Exchange is a resource for U.S. Healthcare Professionals to learn more about disease states investigated by Novo Nordisk and our related products.
The purpose of this site is to provide relevant medical and scientific information about Novo Nordisk products and areas of therapeutic interest. Information about investigational products or investigational uses of approved products neither implies FDA approval for these products or uses, nor establishes the safety or efficacy of these products or uses. There is no guarantee that any investigational product or investigational use will receive FDA approval or become commercially available in the United States. Novo Nordisk does not recommend or suggest use of its products in any manner inconsistent with FDA-approved labeling.
This site is intended for United States healthcare professionals only. The information on this site—including all product information—pertains to residents of the United States only. Any products referenced on this site may have different labelling in different countries.
